Siyata Receives $750,000 Order For Its Next Generation Push-To-Talk Over Cellular Solution

Providing Mission Critical Devices for Large Independent Emergency Medical Service Provider VANCOUVER, BC / ACCESSWIRE / February 21, 2023 / Siyata Mobile Inc. (NASDAQ:SYTA)(NASDAQ:SYTAW) ("Siyata"

Providing Mission Critical Devices for Large Independent Emergency Medical Service Provider

VANCOUVER, BC / ACCESSWIRE / February 21, 2023 / Siyata Mobile Inc. (NASDAQ:SYTA)(NASDAQ:SYTAW(“Siyata” or the “Company”), a global provider of innovative Push-to-Talk over Cellular (“PoC”) and cellular signal booster solutions, today announced it has received an order for $750,000 for its next-generation MCPTT (mission critical push-to-talk) solution to equip an independent emergency management service (“EMS”) provider. The order includes the Company’s SD7 devices and related accessories.

“We continue to gain traction with our push-to-talk product portfolio across multiple industry verticals,” said Marc Seelenfreund, Siyata CEO. “With this order, we will equip the EMS provider’s rescue personnel with our rugged devices, connected across a singular, reliable platform. Our devices, which are well suited to severe conditions, will be used in ambulances, on motorcycles, in various vehicles, in a boat and on a plane in mission critical situations.”

The SD7 enables push-to-talk communications for first responders and enterprise clients in a simple easy-to-use rugged Android based Push-To-Talk (PTT) device with excellent sound quality that operates over the high bandwidth 4G LTE network, providing consistent connectivity across the nation and internationally. Its IP68 rating, resistance to water and dust, drop protection, and robust battery make it well suited for use in harsh environments. Importantly, there is no need to invest in infrastructure such as radio towers or repeaters, and the SD7 allows first responders as well as secondary support personnel to quickly connect and coordinate on unified public cellular networks in North America and international markets.

Users of the SD7 can initiate and receive talk-group calls, receive private calls, notify others of emergencies, and report locations, all actions ideally tailored for mission critical purposes.

Total
0
Shares
Related Posts
Read More

Why Bio-Path Stock Is Soaring

Bio-Path Holdings shares are trading higher Thursday after the company announced the completion of its second dose cohort in Phase 1/1b clinical trial of BP1002 evaluating the ability of BP1002 to treat refractory/relapsed acute myeloid leukemia patients. 

BPTH

Read More

Verastem Oncology Announces Design For Confirmatory Trial Of Avutometinib And Defactinib In Recurrent Low-Grade Serous Ovarian Cancer; As Of March 31, 2023, Verastem Oncology Had Cash And Short-Term Investments Of $111.2M

Randomized Phase 3 Trial (RAMP 301) Will Evaluate the Combination of Avutometinib and Defactinib vs Standard of Care Treatment; Study to Commence in 2H 2023 Recently Published Data from Part A of RAMP 201 Trial Show an

VSTM